TOXICOLOGICAL PROFILE FOR BROMOMETHANE

Agency for Toxic Substances and Disease Registry U.S. Public Health Service

DISCLAIMER

FOREWORD

The Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) extended and amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare toxicological profiles for hazardous substances which are most commonly found at facilities on the CERCLA National Priorities List and which pose the most significant potential threat to human health, as determined by ATSDR and the Environmental Protection Agency (EPA). The lists of the 250 most significant hazardous substances were published in the Federal Register on April 17, 1987; on October 20, 1988; on October 26, 1989; and on October 17, 1990. A revised list of 275 substances was published on October 17, 1991.

Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the lists. Each profile must include the following content:

- (A) An examination, summary, and interpretation of available toxicological information and epidemiological evaluations on the hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects.
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure which present a significant risk to human health of acute, subacute, and chronic health effects.
- (C) Where appropriate, an identification of toxicological testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

This toxicological profile is prepared in accordance with guidelines developed by ATSDR and EPA. The original guidelines were published in the <u>Federal Register</u> on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile is intended to characterize succinctly the toxicological and adverse health effects information for the hazardous substance being described. Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance's toxicological properties. Other pertinent literature is also presented but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

Foreword

Each toxicological profile begins with a public health statement, which describes in nontechnical language a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health will be identified by ATSDR, the National Toxicology Program (NTP) of the Public Health Service, and EPA. The focus of the profiles is on health and toxicological information; therefore, we have included this information in the beginning of the document.

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels, interested private sector organizations and groups, and members of the public.

This profile reflects our assessment of all relevant toxicological testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control, the NTP, and other federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

William L. Roper, M.D., M.P.H.

William L. Roper

Administrator
Agency for Toxic Substances and
Disease Registry

CONTENTS

FORI	EWORI							•													iii
LIST	OF	FIGURES						•													i>
LIST	OF	TABLES		• • •																	хi
1.			TH STATEM]
	1.1	WHAI I	S BROMOME	THANE:		77.01		•		•	•	٠	•		•	•	٠	•	٠	•	
	1.2	HOW MI	GHT I BE	EXPOSE	D TO	BROM	OMET	HAN	EY			•	•	•. •	•	•	•	٠	•	٠	2
	1.3	HOW CA	N BROMOME	THANE	ENTER	AND	LEA	VE	MY	BOI)Y?	,	•		•	•	•	٠	٠	•	4
	1.4	HOW CA	N BROMOME	THANE .	AFFEC	T MY	HEA	LTH	!? .		•	•	•		•	•	•	•	•	•	. 2
	1.5	IS THE	RE A MEDI	CAL TE	ST TC) DET	ERMI	NE	WHE	THI	ER.	I									
		HAVE B	RE A MEDI EEN EXPOS	ED TO	BROMO	METH	ANE?	•				•	•								3
	1.6	WHAT R	ECOMMENDA	TIONS	HAS I	THE F	EDER	AL	GOV	ERI	ME	ENT	M/	ADE	:						
		TO PRO	TECT HUMA	N HEAL	TH? .																3
	1.7	WHERE	CAN I GET	MORE	TNFOR	TTAM	ON?														2
	,	***************************************	0111. 1 021	110111			· · ·	•	•	•	•	•	•	• •	•	·	·	•	•	•	
2.	пруі	TU FFF	CTS																		1
۷.			UIS			• • •	• •	•	• •	•	•	•	•	• •	•	•	.•	•	•	•	-
	2.1	INIKUD	UCTION . SION OF H												•	•	•	•	•	•	
	2.2																				-
		2.2.1		on Exp	osure	•		•		•	•	•	•			•	•	•	•	•	•
			2.2.1.1	Death						•											•
			2.2.1.2	System	mic E	ffec	ts .														20
			2.2.1.3	System Immun	ologi	cal	Effe	cts													2:
			2.2.1.4	Neuro	logic	al E	ffec	ts													2
			2.2.1.5	Devel	onmen	tal	Effe	cts		•	•	•	•		•	•	•	·	•	•	22
			2.2.1.6	Repro	ducti	370 F	$ff_{\Delta C}$	te	•	•	•	•	•	• •	•	•	•	•	•	•	23
			2.2.1.7	Genot	outti	ret.	2+4 TTEC	CS		•	•	•	•		•	•	•	•	•	•	23
			2.2.1.8	Cance																	23
		2.2.2	Oral Exp																		23
			2.2.2.1	Death																	24
			2.2.2.2	Syste	mic E	Effec	ts .														24
			2.2.2.3	Immun	ologi	.cal	Effe	cts													2
			2.2.2.4	Neuro																	27
			2.2.2.5	Devel																	27
			2.2.2.6	Repro	ducti	ve E	ffec	te	•	•	•	•	•	•	·	•	•	•	٠	•	2
			2.2.2.7	Genot	ovio	Effo	2100			•	•	•	•	•	•	•	•	•	•	•	2
			2.2.2.8	Cance																	2
		0 0 0								•	٠	•	•	• •	•	•	•	•	٠	٠	
		2.2.3	Dermal E	-						•	•	•	•		•	•	•	٠	•	•	28
			2.2.3.1	Death																٠	28
			2.2.3.2	Syste	mic E	Effec	ts .			•											28
			2.2.3.3	Immun																	30
			2.2.3.4	Neuro																	30
			2.2.3.5	Devel																	30
			2.2.3.6	Repro																•	3(
			2.2.3.7	Genot																	30
			2.2.3.7																		
	0 0	MOVE CO.		Cance																	30
	2.3							•		•	•	•	•			•	٠	•	•	٠	30
		2.3.1	Absorpti	on .									_						_		30

				Inhalation														30
			2.3.1.2															30
			2.3.1.3															30
		2.3.2	Distribu	tion														31
			2.3.2.1															31
			2.3.2.2		-													31
			2.3.2.3	-														
		2.3.3		sm	<u> </u>													31
		2.3.4		n														32
		2.3.4		Inhalation														32
				Oral Expos														32
			2.3.4.2	Dermal Expos	sure .		•	•	• •		•	•	•	•	• •	•	•	32
	0 4	DET ETA	Z.J.4.J	BLIC HEALT	n hozare		•	•	• •		•	•	•	•	• •	•	•	
	2.4	RELEVA	NCE TO PU	XPOSURE AN	n Derre		•	•	• •		•	•	•	•	• •	•	•	
	2.5	BIOMAK	KERS OF E	XPUSURE AN	D EFFEC	, T	•	,				•	•	•	•	•	•	39
		2.5.1	Biomarke	rs Used to	Identi	ry a	na,	or/	Qua	ıntı	гу							39
			Exposure	to Bromom	ethane	. :	•	•				٠.	•	•	•	•	٠	39
		2.5.2		rs Used to														
			by Bromo	methane .			•				•	•	٠	•			٠	39
	2.6			TH OTHER C														
	2.7			T ARE UNUS														41
	2.8	MITIGA	TION OF E	FFECTS .														41
	2.9	ADEQUA	CY OF THE	DATABASE														42
		2.9.1	Existing	Informati	on on H	lealt	h I	Effe	ects	of	B1	com	om	e tl	har	1e		42
				ds														44
				Studies														49
			0 0															
3.	CHEM	TCAL AN	D PHYSTCA	L INFORMAT	ION													51
٠.	3.1			TY														51
	3.2			EMICAL PRO														
	٥	1111010	ind into on	DITTORIE TICO	1 2111 121	• •	•	•	• •	•	•	•	•	•	•	•	•	
4.	PROD.	HCTTON	TMPORT	USE, AND D	TSPOSAT													55
⊸.	4.1	, מסבדטוני, מסבדטוני	TION		101 00111		•	•	• •	•	•	•	•	•	•	• •	•	55
		TMDODU	/EVDODT			• •	•	•	• •	•	•	•	•	•	•		•	
	4.2	THIFORT	/ EXPORT			• •	•	•		•	•	•	•	•	•	• •	•	55
	4.4	DISPOS	AL			• •	•	•	• •	•	•	•	•	•	•	• •	•	33
_																		
5.				EXPOSURE														
	5.1	OVERV1	EW				•	•		•		٠	•	•	•		•	57
	5.2			ENVIRONME														
		5.2.1	Air					•										57
		5.2.2	Water .															60
		5.2.3	Soil .															60
	5.3	ENVIRO	NMENTAL F	ATE														61
		5.3.1		t and Part														61
		5.3.2	_	mation and		_												61
		· -	5.3.2.1															61
			5.3.2.2	Water .														62
			5.3.2.3	Soil														62
	5.4	TEVETC		D OR ESTIM	ΔΤΕΡ ΤΝ	 J TUE	· E	NT77T	יזא∩ם	MENT	 r	•	•	•	•		•	62
	٠.4																	62
		5.4.1																
		5.4.2																62
		5.4.3																
		5.4.4	Other En	vironmenta	I Media	ı		•		•		•	•					64

	5.5	GENERAL POPULATION AND OCCU																	
	5.6	POPULATIONS WITH POTENTIALLY																	
	5.7	ADEQUACY OF THE DATABASE .																	65
		5.7.1 Data Needs																	65
		5.7.2 On-going Studies .			•		•		•	•	•	•	•	•	•		•	•	67
6.	ANAL	YTICAL METHODS																	69
	6.1	BIOLOGICAL MATERIALS																	69
	6.2	ENVIRONMENTAL SAMPLES																	69
	6.3	ADEQUACY OF THE DATABASE .																	72
		6.3.1 Data Needs																	
		6.3.2 On-going Studies .																	
7.	REGU	LATIONS AND ADVISORIES								•									75
8.	REFE	RENCES																	79
9.	GLOS	SARY			•			•			•								101
APP	ENDIC	ES																	
	Α.	USER'S GUIDE																•	A-1
	В.	ACRONYMS, ABBREVIATIONS, AND	D 8	SYME	OLS	3.										•		•	B-1
	C.	PEER REVIEW																	C-1

•

LIST OF FIGURES

2-1	Levels of Significant Exposure to Bromomethane - Inhalation	15
2-2	Levels of Significant Exposure to Bromomethane - Oral	26
2-3	Existing Information on Health Effects of Bromomethane	43
5-1	Frequency of NPL Sites with Bromomethane Contamination	58

LIST OF TABLES

2-1	Levels of Significant Exposure to Bromomethane - Inhalation	7
2-2	Levels of Significant Exposure to Bromomethane - Oral	25
2-3	Levels of Significant Exposure to Bromomethane Vapor - Dermal	29
2-4	Genotoxicity of Bromomethane <u>In Vitro</u>	37
2-5	Genotoxicity of Bromomethane <u>In Vivo</u>	38
3-1	Chemical Identity of Bromomethane	52
3-2	Physical and Chemical Properties of Bromomethane	53
4-1	Facilities that Manufacture or Process Bromomethane	56
5-1	Releases to the Environment from Facilities that Manufacture or Process Bromomethane	59
5-2	Summary of Bromomethane Levels in Air	63
6-1	Analytical Methods for Determining Bromomethane in Biological Materials	70
6-2	Analytical Methods for Determining Bromomethane in Environmental Samples	71
7-1	Regulations and Guidelines Applicable to Bromomethane	76

...